Beta-Carotene and Eye Health: Why AREDS2 Removed It
Educational summary — not medical advice. This page does not diagnose AMD or any eye condition. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
The original AREDS eye formula included beta-carotene. AREDS2 (2013, JAMA) tested substituting lutein and zeaxanthin instead — specifically because of the ATBC/CARET smoker lung-cancer signal — and found MORE lung cancers in the beta-carotene arm even within this eye-health trial (23 vs 11 cases, concentrated in former smokers), while lutein/zeaxanthin carried no such risk (Chew et al. 2013). That's the direct reason beta-carotene is no longer in the recommended modern AREDS2 formula, and the direct reason this site routes eye-health readers to lutein & zeaxanthin instead.
Why beta-carotene was in the original formula at all
The original AREDS formula (1990s-2000s), based on the first Age-Related Eye Disease Study, included beta-carotene alongside vitamin C, vitamin E, and zinc, reflecting the era's broader antioxidant-supplementation hypothesis — the same general theory that motivated ATBC and CARET. By the time AREDS2 was designed, the ATBC (1994) and CARET (1996) lung-cancer signals in smokers were already well-established, which is exactly why AREDS2's investigators built the trial to test removing beta-carotene and substituting lutein and zeaxanthin, rather than assuming the original formula was safe to continue indefinitely.
What AREDS2 actually found
AREDS2 (Age-Related Eye Disease Study 2 Research Group, 2013, JAMA) enrolled 4,203 adults aged 50-85 at risk of AMD progression, testing added lutein+zeaxanthin and/or omega-3 fatty acids (DHA+EPA) against the base AREDS formula, with median 5-year follow-up. On the primary AMD-progression question, adding lutein/zeaxanthin or omega-3s to the whole cohort showed no significant additional benefit. But the safety comparison is what matters for this page: more lung cancers occurred in the beta-carotene arm than the no-beta-carotene arm — 23 cases (2.0%) vs 11 cases (0.9%) — concentrated in former smokers. This is a second, independent randomized-trial signal pointing the same direction as ATBC and CARET, generated inside a trial that wasn't even designed primarily to study lung cancer. It is the direct reason AREDS2 replaced beta-carotene with lutein and zeaxanthin in the eye formula going forward, and it's a stronger, more current, more citable fact than most competitor pages in this space carry.
What replaced it, and why that's the better answer
Lutein and zeaxanthin are the carotenoids that concentrate specifically in the macula (the central retina), and AREDS2 substituted 10mg lutein + 2mg zeaxanthin for beta-carotene in the modern formula. Whether or not that substitution produced a clean head-to-head efficacy win in the whole-cohort primary analysis, it carried none of the lung-cancer signal beta-carotene showed — and for a supplement combination people are meant to take for years to slow AMD progression, a safety profile with no cancer signal is the decisive factor, not a marginal efficacy difference. See the full lutein/zeaxanthin eye-health breakdown for who AREDS2's evidence actually applies to and what it does and doesn't prove.
The one-line takeaway AREDS2 removed beta-carotene from the modern eye formula because of a lung-cancer signal that showed up inside its own trial arm — not a failed efficacy test. Lutein and zeaxanthin replaced it with no such risk. This site does not recommend beta-carotene for eye health for anyone; see lutein & zeaxanthin for the evidence-based alternative.
Compare Beta-Carotene Products
If you're ready to buy, here's how the beta-carotene products we track and verify compare on cost per dose.
| Product | Dose/Serving | Servings | Price | Cost/Day | Certification | Buy |
|---|---|---|---|---|---|---|
| NOW Foods Natural Beta Carotene 25,000 IU | 15mg beta-carotene | 180 | $21.90 | $0.12 | None stated | Buy on Amazon |
| Pure Encapsulations Beta Carotene (with Mixed Carotenoids) 25,000 IU | 15mg beta-carotene | 90 | $37.00 | $0.41 | Hypoallergenic, NSF-audited GMP | Buy on Amazon |
| Country Life Carotenoid Complex | mg carotenoid blend (not disclosed) | 60 | $27.59 | $0.46 | None stated | Buy on Amazon |
| Karuna Mixed Carotenoids | 7.75mg disclosed carotenoids (lutein+lycopene+zeaxanthin+cryptoxanthin; beta-carotene amount not disclosed) | 30 | $36.60 | $1.22 | None stated | Buy on Amazon |
Frequently asked questions
Why did AREDS2 remove beta-carotene?
More lung cancers occurred in its beta-carotene arm (23 vs 11 cases), concentrated in former smokers — a second, independent RCT signal alongside ATBC and CARET.
Did lutein/zeaxanthin work better?
No clean head-to-head efficacy win in the whole-cohort analysis, but no lung-cancer signal either — the safety comparison drove the substitution.
Should I take beta-carotene for my eyes?
No. This site does not recommend it for eye health for anyone; lutein/zeaxanthin is the evidence-based modern alternative.
Does this apply if I don't smoke?
The signal was concentrated in former smokers, consistent with ATBC/CARET — not evidence it's safe for eye health in non-smokers either.
Related
- Beta-carotene: what the lung-cancer trials showed
- ATBC & CARET, explained in full
- Lutein & Zeaxanthin — what actually replaced beta-carotene in the modern eye formula
- Who AREDS2's evidence actually applies to
Sources
- Age-Related Eye Disease Study 2 Research Group. "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial." JAMA. 2013. PMID: 23644932
- Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. "The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers." New England Journal of Medicine. 1994. PMID: 8127329
- Omenn GS, Goodman GE, Thornquist MD, et al. "Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease." New England Journal of Medicine. 1996. PMID: 8602180